Congenital Adrenal Hyperplasia Clinical Trial
Official title:
A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
This is a 6-week, multiple-dose, dose escalation study of SPR001 for the treatment of adults
with classic CAH. After screening, eligible patients will be enrolled into a 6-week treatment
period followed by a 4-week washout/safety follow-up period.
It is initially planned that up to approximately 18 patients in 2 dose cohorts will be
enrolled. Additional patients or dose groups may be considered based upon specific safety,
PK/PD, and/or efficacy findings, or if an active dose has not yet been reached.
SPR001 will be administered as an oral daily dose. Patients will undergo titration of SPR001
through three escalating dosage strengths at 2-week intervals. Patients will have overnight
PK/PD assessments performed at baseline, which include an pre-dose overnight assessment and a
post-dose overnight assessment for PK/PD following administration of the first dose. At the
end of each 2-week dosing period, patients will return for single overnight visits for
steady-state PK/PD assessments.
A follow-up outpatient visit will occur 30 days after their last dose.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03687242 -
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
|
Phase 2 | |
| Active, not recruiting |
NCT04544410 -
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
|
Phase 2 | |
| Not yet recruiting |
NCT04087148 -
Linear Growth of Children With Congenital Adrenal Hyperplasia
|
||
| Completed |
NCT03162159 -
Adult Height Prediction in Congenital Adrenal Hyperplasia
|
||
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Enrolling by invitation |
NCT05162950 -
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
|
||
| Withdrawn |
NCT03532022 -
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
|
Phase 3 | |
| Recruiting |
NCT02795871 -
Prenatal Dex Study
|
N/A | |
| Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
| Recruiting |
NCT04903587 -
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
|
||
| Not yet recruiting |
NCT04536662 -
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
|
Phase 4 | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Completed |
NCT01807364 -
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
|
N/A | |
| Completed |
NCT02804178 -
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 | |
| Completed |
NCT03019614 -
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
|
Phase 1 | |
| Not yet recruiting |
NCT04293133 -
Final Height in Patients With CAH
|
||
| Recruiting |
NCT03897504 -
Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty
|
N/A | |
| Active, not recruiting |
NCT04806451 -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
|
Phase 3 | |
| Completed |
NCT01875640 -
Decision Support for Parents Receiving Information About Child's Rare Disease
|
N/A | |
| Withdrawn |
NCT00485186 -
Gene Polymorphisms Influencing Steroid Synthesis and Action
|
N/A |